

Whole-Organ Transdermal Photobiomodulation (PBM) of COVID-19: A 50-Patient Case Study

Richard K. Williams^{1*†}, John Raimondo^{2‡}, David Cahn^{3§}, Aldon Williams^{4¶} and Daniel Schell^{5||}

¹*Applied BioPhotonics Ltd, Cupertino, CA, USA*

²*Pulmonair, San Antonio, TX, USA*

³*O'Connor Hospital, San Jose, CA, USA*

⁴*Advanced Spinal Pain Management, Boerne, TX, USA*

⁵*LightMD, Inc., Cupertino, CA, USA*

Abstract

A non-randomized 50-person case study of COVID-19 positive patients was conducted employing (for the first time) a regimen of whole-organ deep-tissue transdermal dynamic photobiomodulation (PBM) as a primary (or exclusive) therapeutic modality in the treatment of coronavirus. Therapy sessions comprised algorithmically alternating red (650 nm) and near infrared (850 nm) LEDs with average irradiance of 11 mW/cm² dynamically sequenced at multiple pulse frequencies. Delivered via 3-D bendable polymeric pads maintaining orthogonal optical incidence to body contours over 1,000 cm², a single 84-min session concurrently delivered 20 kJ to the sinuses and 15 kJ to each lung at skin temperatures below 42 °C. Therapeutic outcomes observed include significant reductions in the duration and severity of disease symptoms. Acute conditions including fever, body aches, and respiratory distress comprising paroxysmal coughing; lung congestion, dyspnea and hypoxia; sinus congestion; acute eye inflammation; and extreme malaise were eliminated in 41/50 patients within 4-days of commencing PBM treatments with 50/50 patients fully recovering within three-weeks with no supplemental oxygen requirements. SpO₂ concentrations improved as much as 9 points (average 2.5 points) across the entire study population. The PBM sessions required to completely resolve COVID-19 conditions appears monotonically correlated to the time-to-treatment (TTTx) — the delay between the onset of a patient's symptoms and commencing PBM therapy. In contrast, acute inflammatory symptoms were resolved within 4-days irrespective of TTTx.

Key words: COVID-19, photobiomodulation, transdermal, mitochondria, ARDS, dyspnea, SpO₂, red/NIR LED

*Corresponding author.

†E-mail: richardwilliams@appliedbiophotonics.com

‡E-mail: drjohnnyray@me.com

§E-mail: clouddc@aol.com

¶E-mail: aldon.williams@yahoo.com

||E-mail: danschell@LightMD.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/jbio.202100194](https://doi.org/10.1002/jbio.202100194)

1 INTRODUCTION

Photobiomodulation (PBM) represents a new and emerging therapeutic modality for the treatment of coronavirus [1] [2] (including COVID-19) and related inflammatory diseases such as pneumonia [3] [4] [5], ARDs [6] [7] [8], COPD [9], and acute lung injury (ALI) [10]. In photobiomodulation therapy, diseased or injured tissue is illuminated by a source of non-ionizing electromagnetic radiation or EMR (delivered via lasers or LEDs) to stimulate physiologically beneficial photochemical reactions. Although small amounts of heat are produced during PBM, the process is photochemical not thermal, invoking biophysical mechanisms offering therapeutic outcomes thermotherapy cannot [11]. Reported PBM benefits include reduced tissue inflammation [12] [13] [14] and dyspnea [15], improved circulation [16], decreased pain [17], and accelerated recovery [18] [19].

PBM is also found to interfere with a pathogen's ability to replicate [20] through innate immune response (via reactive ion species, i.e. ROS) and over longer intervals by regulating adaptive immune response. Other light wavelengths can damage pathogens directly [21] [22] [23], albeit not transdermally in deep tissue or viscera.

PBM can be used adjunctively with other remedies, as a primary therapeutic modality, in palliative care [24] [25], and for prophylaxis [26] [27]. In the treatment of COVID-19 the primary goal of PBM is symptomatic relief – to restore breathing; reduce (or break) fever; ameliorate coughing; mitigate aches and pains; shorten the duration of the viral infection; combat pneumonia or other secondary infections; reduce mucus, edema, and congestion in the bronchia, alveoli, and sinuses; and circumvent the need for ventilation [18]. Compared to pharmacological regimens, PBM is not harmful to kidneys, liver or stomach, and is non-addictive. Unlike antibiotics and antivirals, pathogens cannot develop immunity to photon energy, the “medicine” of photobiomodulation. Unfortunately, the therapeutic administration of PBM by physicians or clinicians today remains problematic, primarily because of fundamental design deficiencies in commercially available PBM apparatus, including both lasers and LED systems.

1.1 Obstacles to Whole Organ PBM:

Without scanning, the characteristically small spot-size of a laser is incapable of concurrent whole-organ PBM treatment, requiring a nurse or specially-trained therapist to constantly hold and manually reposition a handheld probe or wand repeatedly atop the patient dozens-of-times in order to cover a large treatment area. Invariably, this manual operation results in poor energy (dose) uniformity [28] [29] across the lungs, liver, or other large organs. Aside from being uncomfortably slow, the arduous process of manual probing necessitates a nurse spending entire shifts working in extremely close proximity (less than 0.5 m) to severely ill patients and increasing cross infection risks for therapists and patients alike [30] [31]. Moreover, treating the face, sinuses, and upper respiratory tract with laser light unavoidably presents the risk of eye damage or blindness to the patient. Lasers, especially at high power, also pose possible eye injury risks from reflected

light to the nurse administering the treatment [32] [33] [34]. Scanning lasers [35] also suffer from high costs, complex apparatus, fragile optics, and low throughput.

LED-based PBM, in contrast, overcomes the small spot size and safety risk issues associated with lasers, beneficially allowing a treatment to proceed unsupervised after setup. Unfortunately, the optical efficiency of photon delivery in most LED apparatus limits their efficacy, particularly in deep tissue therapy. Specifically, rigid LED panels (along with light beds and light walls) are incapable of significant energy coupling into deep tissue, rendering them unsuitable in the treatment of organs or disease. Unable to maintain a perpendicular angle of incidence along body contours, the majority of optical energy emitted from LED panels is off-axis, lost to reflection, refraction, and scattering in the epithelial layer, never penetrating into the visceral organs where therapy is required.

Studies report a gap of only 2.5-cm between a rigid panel and treated skin loses 94% of the penetrating energy of the impinging photons [36]. As such, rigid light sources are fundamentally unsuitable for deep tissue and large organ therapy. Commercial LED systems also lack the capability of ensuring uniform LED brightness (poor dose control), dynamically controlling pulse modulation rates (for enhancing tissue specificity), sequencing multiple wavelength LEDs (to control penetration depth), or adjusting the array's optical power output (to regulate skin temperature). Together, these PBM parameters represent key factors in controlling PBM total dose – the energy distribution of photons in treated tissue. With these important photonic conditions left uncontrolled, treatments cannot be expected to produce consistent therapeutic outcomes. Furthermore, most LED PBM apparatus do not qualify as medical-grade products as they lack integral failsafe safety systems; have not earned proper medical, GMP and FCC/EMC certifications; and employ porous materials unsuitable for aseptic medical use or regular disinfection.

To our knowledge, this case study is the first to employ a medical-grade LED PBM apparatus designed specifically to overcome the energy-coupling and power control deficiencies of existing systems. As such, the study is the first to evaluate concurrent whole-organ PBM using large-area deep-tissue LED photobiomodulation in the treatment of disease. Specifically, its goal is to determine whether the use of whole-organ dynamic photobiomodulation is capable in the efficacious treatment of COVID-19 and its symptoms.

1.2 PBM Mechanisms of Action:

Photobiomodulation is the biophysical mechanism whereby light of specific wavelengths interacts with biomolecules in living cells and cellular organelles to invoke a photo-chemical reaction with physiological consequences, i.e. photons modulating cellular metabolism. To reach internal organs, the photons must first traverse the body's outer tissue without being absorbed by bodily fluids, water, or blood. Penetrating through the skin into the body cavity, photons impinging on an organ must be absorbed by a specific class of light sensitive molecules to affect physiological function. These photon absorbing molecules, called chromophores [37] [16], generally comprise transmembrane proteins, ion pumps, and ion gates located on the surfaces of, or within, cells and cellular organelles (including mitochondria). Chromophores are biologically ubiquitous, contained in nearly

every living cell and tissue type in animals including neurons, muscles, epithelial, connecting tissue, and vascular systems.

Not all absorbed photons are, however, capable of invoking PBM. Photons carry discrete amounts of energy called quanta, having a magnitude proportional to EMR frequency and inversely proportional to wavelength. Governed by quantum mechanics, absorbed photons must possess a minimum amount of energy to make and break biochemical bonds [38] in order to induce PBM. As a rule-of-thumb, the threshold of PBM corresponds to an energy greater than the energy carried by adenosine-triphosphate (ATP), around 0.6 eV, corresponding to light having wavelengths shorter than 2,000 nm just beyond the near infrared spectrum. So while visible and near infrared light can invoke photobiomodulation, longer wave infrared behaves as heat and does not meet the minimum requirement for PBM [11].

Just because a photon carries sufficient energy to stimulate PBM doesn't mean it can reach an internal organ. Photon transport and absorption within tissue depends on light wavelength. In general, longer wavelength EMR (e.g. infrared and red light) penetrates to greater tissue depths than shorter wavelengths (such as blue, violet, or UV). Contrary to classical Newtonian physics, longer wavelength EMR carries less energy but penetrates more deeply than shorter wavelength higher-energy photons. For photons to reach and then be absorbed by internal organs, tissue must be sufficiently transparent at a given wavelength to allow light to penetrate beyond subdermal layers but be sufficiently opaque to be absorbed by chromophores in the targeted tissue.

If a photon is too long in wavelength (and therefore too low in energy) to invoke PBM, the absorbed light acts like a heat lamp raising the tissue temperature but not stimulating photochemical reactions [39]. At shorter wavelengths however, photons absorbed by chromophores cause photobiomodulation, eliciting electrical, ionic, and chemical transformations within the cell, and releasing waste heat (molecular kinetics) as a byproduct. The magnitude of self heating, however, is minimal. At optical power densities considered safe, i.e. for steady state irradiances below approximately 10-15 mW/cm² of average power, skin temperature is naturally regulated by heart rate, blood perfusion, sweating, and convective cooling to a comfortable 42 °C. Heat however, is not the mechanism-of- action for PBM.

As a photochemical process, PBM involves reactions requiring energy one-to-two orders-of-magnitude greater than the thermal energy available during thermotherapy. As such, thermotherapy cannot produce the same therapeutic outcomes as photobiomodulation. References to PBM as “therapeutic heating” or describing PBM apparatus as heat lamps is scientifically erroneous and phenomenologically misleading. During PBM, waste heat and far infrared (FIR) blackbody radiation may assist in catalyzing reactions thermodynamically to improve chemical kinetics but only as a byproduct of PBM. In other words, some degree of thermotherapy occurs locally in treated tissue during photo- biomodulation.

Given the foregoing penetration and energy requirements, deep tissue PBM required for treating visceral organs is limited to a narrow spectrum of wavelengths in the red and near-infrared portion of the EMR spectrum. Located between the optical absorption wavelengths for water and for deoxygenated hemoglobin, this so-called transparent op-

tical window in animals spans the range from 650 nm to 950 nm. Curiously, the same wavelengths correspond to the reported action spectra of CCO (cytochrome-c oxidase), a light-absorbing chromophore representing the fourth functional group in the electron transport chain of the mitochondrial membrane protein cytochrome-c. Functionally, CCO is responsible for regulating NO; controlling the generation of ATP; maintaining cellular metabolism and homeostasis; and controlling gene expression through nuclear transcription factors (NTFs).

During PBM, light changes the mitochondrial membrane potential (MMP) inducing increased production of ATP and elevating the local concentrations of tissue ROS. Reactive oxide species such as superoxide ($O^{\cdot-}$), NO, and H_2O_2 play pivotal roles in innate immune response irrespective of an invading contagion. Light also affects mast cells, and through degranulation, induces angiogenesis. The role of PBM in stem cell generation and differentiation is only now emerging. Despite this myriad of photochemical pathways, however, it is primarily through mitochondria that PBM modulates cellular metabolism and respiration.

Although mitochondria are believed to be morphologically identical throughout all tissue types, their abundance in various organs and their influence on physiology is tissue specific. For example, in motor and cardiac function mitochondria manage the kinetics of muscle contraction; in signal transduction they control neurons and nociceptors; and in tissue, circulatory and lymph systems they help manage both innate and adaptive immune response. By sensing divalent calcium gradients, mitochondria regulate necrotic (and apoptotic) cell death and replacement (fibroblastic remodeling) in wound repair, neurogenesis, angiogenesis, and bone growth. Ion gate conduction is frequency dependent, involving reaction rates spanning the audio spectrum.

For example, although electron transport and neurological communication react in milliseconds, ion transport across membranes involved in vasodilation, inflammatory response, innate immune response, and homeostatic regulation occur ten to a hundred times slower. By controlling the dynamic modulation rate of PBM to match specific physiological mechanisms and tissue types, and adjusting the treatment regimen accordingly, PBM therapies can be selectively tuned to maximize immune response; suppress inflammatory processes; improve blood perfusion; control cellular necrosis, apoptosis, and phagocytosis; and to stimulate granulation and structural remodeling through fibroblastic repair, thereby expediting the entire inflammatory process of healing. It is for this reason, that continuous wave lasers generally produce subpar results compared to pulse modulated PBM delivery and why no one modulation frequency is best for all organs and tissues. It also explains why PBM response is biphasic, where too much energy delivered too quickly can inhibit rather than promote healing, particularly for high fluence continuous-wave (CW) laser operation. Modulation rate's effect on biphasic response is unknown.

Healing and immune response are even slower. For example ATP synthesis peaks six hours after PBM, while nuclear transcription and protein synthesis involved in tissue repair and adaptive immune response can take 36 to 48 hours following photobiomodulation. PBM therapeutic regimens synchronized to physiological response times, e.g. with sessions administered every two or three days, have been found to be more efficacious than more aggressive treatment schedules.

2 EXPERIMENTAL DESIGN

2.1 Study Strategy:

Given the complex epidemiology of the COVID-19 pandemic and rapidly evolving SARS-CoV-2 genomic variants, over the past year it has become painfully obvious no one-size-fits-all therapeutic stratagem can effectively counter the contagion's infectivity, address its symptomatic diversity, or contain its spread throughout global populations. While some countries are experiencing declines in infection rates (particularly those deploying aggressive vaccination programs), other countries are in the midst of a fourth or even fifth surge.

As such, the intent of this case study is to develop a pragmatic approach to address acute medical conditions associated with the SARS CoV-2 pathogen and its physiological impact, focused on the most dangerous manifestations of the disease, generally those involving severe inflammation, cytokine storms, respiratory distress, low blood oxygen, and the propensity for thrombosis arising from increased blood viscosity. A secondary goal of the study was to determine if the duration of severity and infectivity could be reduced to more quickly free up hospital beds, essentially increasing hospital capacity without incurring the cost or delays of new infrastructure.

Under medical standards of care and compassionate use, therapies known to produce beneficial therapeutic outcomes cannot ethically be withheld from patients seeking urgent relief. In the midst of a pandemic outbreak, therefore, the incoming patients should not be denied treatment just to maximize a target test population or to select a specific set of conditions. Accordingly, patients were treated without regard to meeting defined study criteria, irrespective of comorbidities. Instead, the population of treated patients was analyzed in accordance with well-established symptomatic criteria of COVID-19 comprising three broad and non-exclusive categories of predominant conditions, namely (i) pulmonary distress, (ii) upper respiratory infection, and (iii) other symptoms.

Patients experiencing pulmonary distress include acute bronchitis, severe coughing; shortness of breath; low SPO₂ levels; pneumonia, and/or COPD or ARDs-like symptoms; chest pain; and increased lung opacity in chest X-rays. Upper respiratory distress includes severe sinus congestion and rhinitis; sore throat; choking; excessive mucus; burning, itching, and inflamed eyes; blurry vision; severe sinus congestion; and persistent headache. The category "other symptoms" primarily comprise gastrointestinal distress including nausea; vomiting; diarrhea; stomach cramping; painful urination; kidney pain, or persistent abdominal discomfort. Fever, restless sleep, and malaise were not indicative as these symptoms were common to all groups treated.

2.2 PBM Apparatus:

In this study, whole-organ dynamic photobiomodulation therapy was performed using the ABPT1003 phototherapy system specified, designed, and manufactured by Applied Bio-Photonics Ltd. comprising a software-based dual-output controller driving up to six 3D-bendable silicone pads containing dense arrays of LEDs. The PBM controller comprises medically-rated galvanically-isolated offline power supplies; redundant safety systems;

graphical UI/UX with color LCD touchscreen and hierarchical menu; and a microprocessor- controlled LED drive system for dynamically sequencing LED wavelengths and modulating frequencies in accordance with defined algorithms. In operation, modulating pulse frequency, optical power density, and skin temperature are actively controlled using pulse-width-modulation (PWM) with nanosecond precision in accordance with predefined treatment or session protocols.

Optical energy is delivered by 3-D bendable LED pads containing arrays of red and near-infrared LEDs having wavelengths of 650 nm and 850 nm respectively, within the aforementioned transparent optical window corresponding to reported action spectra of CCO. During conduction, LED current is maintained at constant levels independent of stochastic variations in LED forward voltages or component aging, facilitating precise brightness consistency and uniformity within a pad, from pad-to-pad, and from one manufacturing batch to another. During therapy, skin temperature maintains 42°C in equilibrium, safely delivering the maximum power density in steady-state operation. The optical power level may also be adjusted for cooler tissue temperatures as desired for patient comfort. Collectively, the system's six LightPads containing an array over twelve-hundred LEDs covering up to a total conformal surface area of more than 1,200 cm². The large pad treatment area facilitates concurrent treatment of whole organs (such as a lungs and sinuses shown in Fig. 1) without need for scanning or for a therapist to manually hold or reposition the light source during therapy.




FIGURE 1: Schematic representation of anterior positioning of LED pads atop sinuses and lungs [attribution: Encyclopedia Britannica (human body)]¹

The specially designed LED pads bend in three-dimensions, conforming to body contours to maintain orthogonal optical incidence, preventing energy loss or reduction in penetration depth due to reflection, refraction, and surface scattering. Except for a transparent plastic or silicone sanitary barrier, the LED pads fit snugly against the body with virtually no gap. The device is approved in the US FDA, Taiwan FDA, Dubai Health Authority (DHA), and UAE Ministry of Health (MOH), and certified for manufacturing

made in accordance with US and Taiwan GMP (Good Manufacturing Practice) standards. The manufacturer passed a one-week random audit by the US FDA including an exhaustive review of the product's Design History File (DHF), Device Master Record (DMR), TQM quality systems, and onsite factory audits. The device is FDA GUDID registered. Independent safety certifications include CE, ISO-13485, IEC-62471 photobiological safety, and FCC approval for electromagnetic compatibility (EMC). The PBT system (including controller, LED pads, and dynamic algorithms) are covered by an IP portfolio comprising 21 issued USPTO, EPO and international patents with another dozen pending.

2.3 PBM Therapeutic Regimen:

Considering COVID shelter-in-place provisions during the 2020 outbreak, patients in the study were treated on an outpatient basis in well-ventilated areas rather than in hospitals and indoor clinics, thereby eliminating risks of patient-to-patient cross infection. To minimize direct contact with the administering physician, patients maintained a physical separation from the doctor as facilitated by two-meter long electrically-shielded cables connecting the LED pads to the PBM controller. No doctors or therapists became infected during this study.

During pre-treatment setup, patients were instructed to position two sets of pads on their anterior, one set-of-three pads covering their lungs, the second set-of-two (or three) pads placed across the face, eyes, and sinuses as shown previously in Fig. 1. All pads were driven concurrently using identical treatment algorithms comprising fully-automated dynamic sequencing of red and NIR LEDs modulated at predefined pulse patterns developed to address specific physiological conditions. Each session involved a series of treatments comprising the following protocol intended to:

1. Stimulate immune response locally and systemically (24 min)
2. Increase local circulation in treated organs and tissue (20 min)
3. Promote homeostasis in treated organs and tissue (20 min)
4. Relieving inflammation in treated organs and tissue (20 min)

Requiring 84 minutes to complete, at 11 mW/cm² each session delivers 50 J/cm². For patient comfort, steps 3 and 4 can be shortened by ten minutes each as required with minimal impact on therapeutic efficacy. The specified therapeutic regimen involves performing one session every two-or-three days until the patient experiences significant relief.

2.4 Study Population:

In this study, 67 patients were recommended for treatment on referral basis. Of the incoming patient population, 50 symptomatic individuals tested positive for COVID while another 9 individuals were symptomatic but unconfirmed for coronavirus infection (either being untested or initially receiving a negative COVID test outcome). Another 8 untested

patients were asymptomatic but had been in direct contact with symptomatic COVID- positive patients, and requested to be treated prophylactically. In accordance with medical standards of care, all 67 patients were (as requested) accepted for and treated with PBM therapy. Only the 50 incoming patients testing COVID-positive, however, were considered as members of the non-randomized case study.

Treatments were administered by physicians and/or under doctor supervision. Using ethical standards for compassionate care, all patients requesting therapy were treated free of charge and without regard to their severity, age, or demographics. No patient was recruited or encouraged to receive PBM therapy, nor was any compensation or payment made to any patient receiving PBM therapy. Of their own volition (or after discussions with their personal physician) all candidates chose PBM as their primary therapeutic modality and elected not to be hospitalized. As such, no chest X-rays were taken or available for the patients treated. Prior to therapy, COVID-19 positive patients were categorized in levels of increasing physiological distress, identified by five degrees of symptomatic severity, from mild to severe. Consistent with the observed pathology of COVID-19 disease progression, the degrees of severity are herein referred to as “stages”. The non-randomized sample population of all patients and the identified case study members is represented in Fig. 2.




FIGURE 2: Patient and case-study population statistics

Disease symptoms for COVID-19 included malaise; dyspnea; cough; taste & smell loss; sinus inflammation; headaches (HA), body aches (BA); abdominal discomfort (AbD) or cramping; fever; and depressed SpO₂ levels. A statistical analysis of symptoms in the incoming COVID-19 patient population “n” is summarized in Table 1.

General observations regarding the COVID-19 patients include the following: 100% of all patients were confirmed by rapid test to be infected with COVID-19.

- 50/50 patients were symptomatic, with 34% severe or moderately-severe.
- 90% of all patients suffered malaise.

TABLE 1
Table 1: Observed conditions for incoming COVID

Stage	n	Condition	COVID	TTTx	Malaise	Dyspnea	Cough	T&S- Loss	Sinus Inflam	Aches/Pain	Temp °F	SpO ₂	HR
1	6	Mild	Y	22.5	2/6	0/6	2/6	1/6	4/6	HA	98.9	99	75
2	16	Mild-to- Moderate	Y	2.0	15/16	1/16	11/16	1/16	6/16	HA	100.0	96	76
3	11	Moderate	Y	2.7	11/11	0/11	9/11	1/11	7/11	BA,HA,AbD	100.1	96	77
4	10	Moderate- to-Severe	Y	4.0	10/10	2/10	9/10	2/10	6/10	BA,HA,AbD	100.4	93	82
5	7	Severe	Y	7.8	7/7	6/7	6/7	1/7	5/7	BA,HA,AbD	100.4	89	85
All	50	All	Y	-	45/50	9/50	37/50	6/50	28/50	BA,HA,AbD	-	-	-

- 40/50 patients had fever, 26% with temperatures of ~101°F (38 °C), the highest fever observed.
- 40/50 patients experienced body aches (BA) & pains, 100% of BA correlated with fever.
- 9/50 patients suffered shortness of breath or wheezing (dyspnea), mostly in severe stages.
- 37/50 patients had a cough, 30% of which was severe.
- 28/50 patients had rhinitis, sinus congestion, and upper respiratory distress.
- 1/50 patients experienced severe eye inflammation.
- 2/50 patients had mild nausea, 3/50 reported abdominal distress and cramping (AbD)
- No patients in the study were on mechanical ventilators.
- Three patients supplemented room air with 6L/min pure oxygen (100% FiO₂).

Analysis of measured and reported symptoms in the table show Stage-1 is characterized by sinus infection and a low-grade fever but minimal coughing or lung dysfunction (as evidenced by a SpO₂ of 99). For the case study patients, the data suggests initial COVID infection occurred in the sinuses and not in the lungs, bronchial passages, or alveoli.

Stage-2, a mild-to-moderate degree of severity, is predominantly identifiable by a significant increase in coughing, the onset of 100 °F (37.8 °C) fever, and a 3-point decline in SpO₂ with a corresponding sense of worsening malaise. Although sinus inflammation persists, this stage appears to chronicle the migration of the infection from the sinuses into the lungs. In the moderate Stage-3, a dry and hacking cough becomes pervasive while sinus inflammation and malaise continue. Persistent fever brings with it chills, body aches, headaches and some abdominal cramping, but minimal reports of nausea. Stage-4, the onset of moderately-severe acute symptoms sees another 3-point decline in SpO₂, a slightly higher degree of fever, widespread malaise, coughing and sinus congestion, and the first reported incidences of dyspnea.

Stage-5, the severe acute disease phase, exhibits nearly universal symptoms of dyspnea and coughing fits along with a precipitous drop in SpO₂ into the 80s. In its mature infectious stage, COVID patients reportedly exhibit severe constriction of the bronchial passageways, lung congestion, and possible organ damage (including the formation of scar tissue) consistent with dyspnea, low blood oxygen, coughing, and chest pain. In one patient, even the smallest cough provoked painful paroxysmal 20-minute coughing fits and an associated shortness of breath. In another patient, persistent sinus congestion further led to severe inflammation of the conjunctiva and mucus membranes surrounding both eyes, but especially in their left eye. No subjects exceeding Stage-5 were studied as these patients were already hospitalized and not available for PBM treatments.

3 RESULTS

The following Table 2 represents the distribution of therapeutic results of PBM treatments as categorized and arranged by stages. The table contains the population n of each group, confirmation of a COVID-positive test for all patients in the study, the range (and average) time-to-treatment TTTx (in days) for each group, the range (and average) number of PBM sessions performed on each group, the total time TTAR (in days) for relief of acute symptoms and a description of the symptoms relieved, and average of the total time TTFR for full recovery of the entire population of the group, and the corresponding range (and average) measured change in SpO₂ for the group over the full course of the study.

As shown in Fig. 3, a histogram of the number of treatments performed for the COVID-positive case study group was limited to a maximum of three sessions for Stage 1 through Stage 4 patients. In contrast, 2/7 of Stage-5 patients required a greater number of PBM sessions (specifically 7 and 9 sessions) to restore normal breathing and sustained blood oxygen levels. Out of a preponderance of caution, one of these patients suffering severe lung dysfunction concurrently received a six-day steroidal course as an anti-inflammatory supplement to their PBM regimen.




FIGURE 3: Histogram of number of PBM sessions performed to patient full recovery The data reinforces the general

premise that left unchecked, COVID-19 is selective, causing severe lung damage and dyspnea in a subset, but not all, of the infected population – especially to those sensitive to severe inflammation with a propensity for cytokine storms and autoimmune response. Another measure of lung dysfunction is evidenced by observed improvement in SpO₂ levels during PBM and their correlation to the various stages of s disease’s progression as shown in Fig. 4. For patients suffering severe dyspnea and low oxygen saturation, PBM is shown to increase SpO₂ by as much as 15 points, from 84 to 99.

In general, the rapidity by which a patient is able to fully recover from symptomatic

TABLE 2
Summary of therapeutic results of PBM sessions

Stage	n	Condition	COVID+	TTTx (ave)	#-of- sess	Sess (ave)	TTAR	Acute Relief	TtFR	Final Δ SpO ₂	Δ SpO ₂ (ave)
1	6	Mild	Y	2.5	1	1.0	1.0	Sinus, HA	2.0	0-1	0.0
2	16	Mild-to-Moderate	Y	2.0	1-2	1.1	0.9	Fever, cough, sinus, HA	1.6	0-4	1.7
3	11	Moderate	Y	2.7	1-3	1.6	1.0	Fever, cough, sinus, HA/BA	3.5	0-3	1.0
4	10	Moderate-to-Severe	Y	4.0	1-3	2.1	1.0	Fever, cough, sinus, HA/BA	4.0	2-6	4.0
5	7	Severe	Y	7.8	1-9	3.0	1.3	Dyspnea, fever, cough, sinus	6.0	3-15	6.6




FIGURE 4: Observed increase in SpO₂ from PBM regimen for progressive stages of COVID-19

COVID-19 infections depends on how long they are ill before taking action, i.e. time to full recovery (TFR) monotonically correlates with the time-to-treatment TTTx. This correlation is shown by the dashed line and circle markers in the scatter plot of Fig. 5 which illustrates treatments performed within a week of the first symptoms of COVID-19 can be resolved within 8 days and most within 4 days. By delaying treatment full recovery of unventilated patients can take nearly three weeks to substantially resolve.

Curiously, the time required to substantially ameliorate acute COVID-19 symptoms (shown by the solid line and square markers) occurs quickly, in approximately 3-4 days irrespective of the TTTx time lag before commencing treatment. Acute condition relief of COVID-19 includes breaking fever; improving breathing; reducing painful dry coughing; eliminating sinus congestion, and relieving severe eye inflammation. For example, a Stage-5 COVID-19 patient suffering severe eye inflammation showed significant reduction in inflammation of the conjunctiva and mucous membranes of the eye after two PBM sessions in a four-day interval, as shown in Fig. 6.

Another aspect of dynamic PBM used in this study is the application of sequential algorithmic variable-frequency treatment protocols. As described in the Therapeutic Regimen section of this paper, each treatment phase performs a different role therapeutically. Consistent with published literature, this study reinforces the argument for frequency dependent tissue specificity. For example, one patient suffering severe dry cough and dyspnea, experienced coughing fits continuing unabated for 20 seconds causing significant breathing distress. Although, during PBM the coughing continued throughout the first phase of the therapy intended to systemically enhance immune




FIGURE 5: Scatter plot of time-to-acute-relief (TTAR) and time-to-full-recovery (TTFR) versus time-to-treatment (TTTx)



FIGURE 6: Reduction of eye inflammation after two PBM sessions

response, immediately after commencing the phase for enhancing circulation, the patient's coughing suddenly decreased by 95%, anecdotally reinforcing the premise that in dynamic PBM, different modulation frequencies enhance tissue specificity.

4 DISCUSSION

The profoundly different time scales for acute relief time TTAR and full recovery time TTFR and their distinct dependences on time-to-treatment TTTx suggests that different biophysical mechanisms are involved in the acute and long-term recovery phases for COVID-19 using therapeutic photobiomodulation. Specifically, the nearly immediate relief of acute conditions, irrespective of the time a patient was COVID-19 symptomatic before commencing therapy, suggests activation of photochemical processes not related to nuclear transcription factors or gene expression. Mechanistically, the absorption of photons by the mitochondrial chromophore and transmembrane protein CCO is known to rapidly release NO resulting in vasodilation, increased tissue and blood oxygen levels, and enhanced circulation.

This effect, combined with a propensity for erythrocytes to become negatively charged during PBM and thereby resisting clumping (through repelling electrostatic force), enhances blood perfusion and reduces the chance of thrombosis, edema, and hypoxemia-induced tissue necrosis in the bronchia and alveoli. By suppressing local inflammation, enhanced circulation also helps avoid an overreaction of the immune system precipitating a dangerous cytokine storm.

Concurrently, the release of super-oxides, H₂O₂, and other reactive oxygen species (ROS) during PBM initiates an immediate innate immune response, able to directly attack invading viral pathogens such as coronavirus at the molecular level while preventing the onset of secondary bacterial infections. The innate immune response is further assisted kinetically by a rapid increase in cellular metabolism resulting from a higher MMP (mitochondrial membrane potential) during PBM and a consequential rate increase in ATP production, peaking six hours after a treatment.

In contrast, full recovery from a COVID-19 infection requires repair of the damage to the lungs, mucus membranes, and other epithelial tissue caused by the viral infection starting by removing dying or damaged cells and scar tissue. Effecting tissue repair involves nuclear transcription to produce enzymes, proteins, and catalysts needed to expedite the healing process including inflammation, regeneration and remodeling of damaged tissue, and to selectively perform cellular necrosis, phagocytosis, and fibroblastic regrowth. The cumulative magnitude of damage to be repaired is therefore proportional to the time a patient was infected and symptomatic before commencing PBM. And since a greater degree of tissue repair takes longer, it is not surprising the time to full recovery TTFR would be monotonically proportional to the time-to-treatment TTTx while time to acute relief TTAR is not.

5 CONCLUSIONS

A therapeutic PBM protocol comprising a single 84-minute concurrent treatment of the sinuses and anterior lungs using whole-organ dynamic photobiomodulation has demonstrated significant promise in the symptomatic treatment of COVID-19. Performing PBM on a 50-person non-randomized sample of symptomatic unventilated COVID-19 patients using PBM resulted in all 50-patients fully recovering symptom free within three weeks, with the majority of the sample population recovering within four days. The PBM therapeutic modality offers numerous advantages over pharmacological regimens and exhibits no adverse side effects on the kidneys, liver or stomach.

Although early treatment was found to reduce the severity of the disease and shorten the time to full recovery, the time required to deliver immediate symptomatic relief of acute conditions was less than 2-to-3 days and generally required only a single PBM session irrespective of the time a patient was COVID-19 symptomatic before commencing therapy. Acute symptoms ameliorated by PBM include improving breathing; reducing painful dry coughing; breaking fever; eliminating sinus congestion, and relieving severe eye inflammation. The time required to fully recover from all residual effects of a COVID-19 infection, however, was longer – taking up to three weeks in duration roughly proportional to the interval when a patient first became COVID symptomatic until the time when PBM therapy commenced. The use of whole-organ dynamic photobiomodulation delivered via 3D-conforming LED pads shows promise as a therapeutic regimen in the non-pharmacological treatment of COVID-19.

Given the significant recovery (50/50) of COVID-positive patients to PBM therapy demonstrated in this study, the use of whole-organ dynamic photobiomodulation is favorably indicated for the symptomatic relief of COVID-19.

Although further research is needed to optimize treatment protocols (and ideally shorten session times to one hour), an emergency use authorization for this treatment to combat the ongoing COVID-19 pandemic is warranted. Moreover, the widespread application of the PBM protocols described herein delivered through outpatient therapy, clinics, or in acute care centers can relieve hospital overcrowding during pandemic surges, both by reducing the number of severely ill patients and by shortening recovery from severe symptoms to under four days.

6 CONFLICTS OF INTEREST

No doctors involved in this study are shareholders, employees, or paid consultants of Applied BioPhotonics Ltd. (ABP), the device manufacturer, system specifier, and IP holder. No doctors received compensation from ABP to participate in this study. No patients paid for receiving PBM therapy in this study. No patients requesting therapy were turned away from receiving treatments.

LightMD Inc. is the US FDA registered, licensed importer and distributor of ABP products in the United States.

ACKNOWLEDGMENTS

The authors would like to thank Laura E. Williams for her support in the research of this project.

References

- [1] Sigman, S.A., Mokmeli, S., and Vetrici, M.A. (2020) Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: A case report. *Can J Respir Ther*, **56**, 52–56. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521601/>.
- [2] Nejatifard, M., Asefi, S., Jamali, R., Hamblin, M.R., and Fekrazad, R. (2021) Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review. *Cytokine*, **137**, 155312–155312, doi:10.1016/j.cyto.2020.155312. URL <https://dx.doi.org/10.1016/j.cyto.2020.155312>.
- [3] (2020), COVID-19 pneumonia patient shows significant improvements following laser treatment at Massachusetts hospital. URL https://www.wfmz.com/news/pr_newswire/pr_newswire_health/covid-19-pneumonia-patient-shows-significant-improvements-following-laser-treatment-at-massachusetts-hospital/article_812f6188-56c1-5044-8417-9b849948a9c3.html.
- [4] Sigman, S.A., Mokmeli, S., Monici, M., and Vetrici, M.A. (2020) A 57-year-old African American man with severe COVID-19 pneumonia who responded to supportive photobiomodulation therapy (PBMT): first use of PBMT in COVID-19. *American J. Case Reports*, **21**, 1–7, doi:10.12659/AJCR.926779. URL <https://pubmed.ncbi.nlm.nih.gov/32865522/>.
- [5] Vetrici, M.A., Mokmeli, S., Bohm, A.R., Monici, M., and Sigman, S.A. (2021) Evaluation of adjunctive photobiomodulation (PBMT) for COVID-19 pneumonia via clinical status and pulmonary severity indices in a preliminary trial. *Journal of Inflammation Research*, **14**, 965–979, doi:10.2147/jir.s301625. URL <https://dx.doi.org/10.2147/jir.s301625>.
- [6] da Silva Sergio, L.P., Thomé, A.M.C., da Silva Neto Trajano, L.A., Mencalha, A.L., de Souza da Fonseca, A., and de Paoli, F. (2018) Photobiomodulation prevents DNA fragmentation of alveolar epithelial cells and alters the mRNA levels of caspase 3 and Bcl-2 genes in acute lung injury. *Photochem Photobiol Sci*, **17** (7), 975–983. URL <https://pubmed.ncbi.nlm.nih.gov/29922788/>.
- [7] Gunn, C. (2005) Acute respiratory distress syndrome successfully treated with low level laser therapy. *J Comp Integ Med*, **2** (1), 5–5. URL <https://www.degruyter.com/document/doi/10.2202/1553-3840.1019/html>.
- [8] Soheilifar, S., Fathi, H., and Naghdi, N. (2020) Photobiomodulation therapy as a high potential treatment modality for COVID-19. *Lasers Med Sci*, pp. 1–4, doi:10.1007/s10103-020-03206-9. URL <https://dx.doi.org/10.1007/s10103-020-03206-9>.

- [9] de Souza, G.H.M. *et al.* (2020) Acute effects of photobiomodulation therapy applied to respiratory muscles of chronic obstructive pulmonary disease patients: a double-blind, randomized, placebo-controlled crossover trial. *Lasers Med Sci*, **35** (5), 1056–1063, doi:10.1007/s10103-019-02885-3. URL <https://read.qxmd.com/read/33241526/photobiomodulation-therapy-as-a-high-potential-treatment-modality-for-covid-19?sid=dbe15a7e-4d80-4680-9cd1-7d398f38995a>.
- [10] da Palma-Cruz, M., da Silva, R.F., Monteiro, D., Rehim, H.M.M.A., Grabulosa, C.C., de Oliveira, A.P.L., and dos Santos-Franco, A.L. (2019) Photobiomodulation modulates the resolution of inflammation during acute lung injury induced by sepsis. *Lasers Med Sci*, **34** (1), 191–199, doi:10.1007/s10103-018-2688-1. URL <https://pubmed.ncbi.nlm.nih.gov/30443882/>.
- [11] Williams, R.K. (2020), Biomedical mechanisms of photobiomodulation therapy & thermotherapy: modalities and misconceptions. URL <http://www.appliedbiophotonics.com/library>.
- [12] Moskvin, S., Askhadulin, E., and Kochetkov, A. (2021) Low-level laser therapy in prevention of the development of endothelial dysfunction and clinical experience of treatment and rehabilitation of COVID-19 patients. *Rehab Res Pract*, **2021** (6626932), 1–8, doi:10.1155/2021/6626932. URL <https://www.hindawi.com/journals/rerp/2021/6626932/>.
- [13] Sherafat, S.J., Razaghi, Z., Rostami-Nejad, M., Tavirani, M.R., and Razzaghi, M. (2020) The effectiveness of photobiomodulation therapy (PBMT) in COVID-19 infection. *J Lasers Med Sci*, **11**, S23–S29. URL <https://journals.sbmu.ac.ir/jlms/article/view/32600>.
- [14] Fazza, T.F. *et al.* (2020) Effect of low-level laser therapy on the inflammatory response in an experimental model of ventilator-induced lung injury. *Photochem. & Photobio. Sci*, **19** (10), 1356–1363, doi:10.1039/d0pp00053a. URL <https://pubmed.ncbi.nlm.nih.gov/32761018/>.
- [15] Marchi, T.D. *et al.* (2020), Effects of photobiomodulation therapy combined with static magnetic field (PBMT-SMF) in patients with severe COVID-19 requiring intubation: a pragmatic randomized placebo-controlled trial, doi:10.1101/2020.12.02.20237974. URL <https://www.medrxiv.org/content/10.1101/2020.12.02.20237974v2.full>.
- [16] de Freitas, L.F. and Hamblin, M.R. (2016) Proposed mechanisms of photobiomodulation or low-level light therapy. *IEEE J Sel Top Quantum Electron*, **22** (3), 7000–7000, doi:10.1109/JSTQE.2016.2561201. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215870/>.
- [17] Williams, R.K. (2017) Advances in photobiomodulation therapy - a new paradigm in pain management. *4th Intl Conf Pain Med (invited) - J Pain Relief*, **6**, 6–6, doi:10.4172/2167-0846-C1-016. URL <https://www.omicsonline.org/conference-proceedings/2167-0846-C1-016-003.pdf>.

- [18] Mokmeli, S. and Vetrici, M. (2020) Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19. *Canadian J Resp Ther*, **56**, 25–31, doi:10.29390/cjrt-2020-015. URL <https://dx.doi.org/10.29390/cjrt-2020-015>.
- [19] Brochetti, R.A., Leal, M.P., Rodrigues, R., and Palma, R. (2017) Photobiomodulation therapy improves both inflammatory and fibrotic parameters in experimental model of lung fibrosis in mice. *Lasers Med Sci*, **32** (5), 1825–1834, doi: 10.1007/s10103-017-2281-z. URL <https://pubmed.ncbi.nlm.nih.gov/28712048/>.
- [20] Hanna, R., Dalvi, S., Sălăgean, T., and Bordea, I.R. (2020) Phototherapy as a rational antioxidant treatment modality in COVID-19 management. *New Concept and Strategic Approach: Critical Review*, **9** (19), 875–898, doi:10.3390/antiox9090875. URL <https://pubmed.ncbi.nlm.nih.gov/32947974/>.
- [21] Zupin, L., Gratton, R., Fontana, F., Clemente, L., Pascolo, L., Ruscio, M., and Crovella, S. (2021) Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells. *J Biophotonics*, **14** (4), 1–8, doi:10.1002/jbio.202000496. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995021/>.
- [22] Sabino, C.P. *et al.* (2020) Light-based technologies for management of COVID-19 pandemic crisis. *J Photochemistry & Photobiology, B: Biology*, **212** (111999), 1–8, doi:10.1016/j.jphotobiol.2020.111999. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435279/>.
- [23] Enwemeka, C.S., Bumah, V.V., and Masson-Meyers, D.S. (2020) Light as a potential treatment for pandemic coronavirus infections: A perspective. *J Photochem Photobiology B: Biology*, **207** (111891), 1–7, doi:10.1016/j.jphotobiol.2020.111891. URL <https://dx.doi.org/10.1016/j.jphotobiol.2020.111891>.
- [24] Fornaini, C., Merigo, E., Huffer, K.W., and Arany, P. (2021) At-home photobiomodulation treatments for supportive cancer care during the COVID-19 pandemic. *Photobiomodulation, photomedicine, and laser surgery*, **39** (2), 81–82, doi: 10.1089/photob.2020.4923. URL <https://pubmed.ncbi.nlm.nih.gov/32905736/>.
- [25] Faria, K.M. *et al.* (2020) Impact of pandemic COVID-19 outbreak on oral mucositis preventive and treatment protocols: new perspectives for extraoral photobiomodulation therapy. *Supportive Care in Cancer*, **28** (10), 4545–4548, doi:10.1007/s00520-020-05636-1. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372978/>.
- [26] Williams, R.K. (2020), Infectious disease outbreaks in spring 2020: the role of photobiomodulation in health maintenance. URL www.appliedbiophotonics.com/library.
- [27] Pelletier-Aouizerate, M. and Zivic, Y. (2021) Early cases of acute infectious respiratory syndrome treated with photobiomodulation, diagnosis and intervention: Two case reports. *Clinical Case Reports*, **9** (4), 2429–2437, doi:10.1002/ccr3.4058. URL <https://dx.doi.org/10.1002/ccr3.4058>.

- [28] Arany, P. (2019), Phototherapy: Photobiomodulation therapy-easy to do, but difficult to get right. URL <https://www.laserfocusworld.com/lasers-sources/article/14037967/photobiomodulation-therapyeasy-to-do-but-difficult-to-get-right>.
- [29] Khan, I. and Arany, P.R. (2016) Dosimetry for photobiomodulation therapy: re-sponse to Sommers et al. *Annals Translational Med*, **4** (10), 208–213, doi:10.21037/atm.2016.05.34. URL <https://atm.amegroups.com/article/view/10516/html>.
- [30] Nguyen, L.H., Drew, D.A., Graham, M.S., Joshi, A.D., Guo, C.G., Ma, W. *et al.* (2020), Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study, doi:10.1016/S2468-2667(20)30164-X. URL [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(20\)30164-X/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30164-X/fulltext).
- [31] Ortega, J. and González, J.M. (2020), Nursing in the time of COVID-19: Two advanced practice nurses on the front lines of the pandemic. URL <https://www.paho.org/en/stories/nursing-time-covid-19-two-advanced-practice-nurses-front-lines-pandemic>.
- [32] Smalley, P.J. (2011) Laser safety: risks, hazards, and control measures. *Laser Therapy*, **20** (2), 95–106, doi:10.5978/islsm.20.95. URL <https://dx.doi.org/10.5978/islsm.20.95>.
- [33] (2021), Laser safety for clinical applications. URL <https://ilchiro.org/laser-safety-for-clinical-applications/>.
- [34] Annis, F. (2021), Five important laser safety measures to follow. URL <https://blog.universalmedicalinc.com/laser-safety-important-safety-measures-to-follow/>.
- [35] (2020), Doctors in Lowell, Mass., report positive outcomes for second COVID-19 patient treated with laser therapy. URL <https://www.prnewswire.com/news-releases/doctors-in-lowell-mass-report-positive-outcomes-for-second-covid-19-patient-treated-with-laser-therapy-301139656.html>, Press Release via Cision PRN Newswire .
- [36] Anders, J. (2017), Photobiomodulation therapy comes of age. URL https://www.photonics.com/Articles/Photobiomodulation_Therapy_Comes_of_Age/a61531.
- [37] Hamblin, M.R. (2018) Mechanisms and mitochondrial redox signaling in photobiomodulation. *Photochemistry and Photobiology*, **94** (2), 199–212, doi:10.1111/php.12864. URL <https://dx.doi.org/10.1111/php.12864>.
- [38] Brumer, P. and Shapiro, M. (2012) Molecular response in one-photon absorption via natural thermal light vs. pulsed laser excitation. *Proc Natl Acad Sci*, **109** (48), 19 575–19 578, doi:10.1073/pnas.1211209109. URL <https://dx.doi.org/10.1073/pnas.1211209109>.
- [39] Khumalo, B. (2019) What is heat; the photon is heat. *J Advances in Physics*, **15**, 6018–6038, doi:10.24297/jap.v15i0.7896. URL <https://dx.doi.org/10.24297/jap.v15i0.7896>.